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Summary The relationship between two methods of assessing tumour oxygenation in vivo, namely oxygen electrode measurement and
magnetic resonance spectroscopy (MRS) of the fluorinated 2-nitroimidazole SR-4554, was investigated. Using three tumour models (two
sites), no linear correlation was observed between 19F retention index and P02 parameters (r < 0.3). Substantial retention of SR-4554 (19F
retention index > 0.5) was, however, associated with low tumourP02 (%P02 < 5 mmHg = 60%). Depending on theP02 parameters used, SR-
4554 administration was shown to produce either a significant or a non-significant increase in tumour oxygenation. We conclude that
measurement of SR-4554-related compound(s) by 19F-MRS has the potential to detect clinically relevant levels of tumour hypoxia.
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Currently, the oxygen tension (pO2) within tumours can be
measured directly by fine needle oxygen electrodes (Kolstad,
1968; Vaupel et al, 1992; Okunieff et al, 1993; Horsman et al,
1994; Brizel et al, 1995; Nordsmark et al, 1995). Such measure-
ments have been used clinically to investigate the effect oftumour
oxygenation on the radiocurability of human tumours (Kolstad
1968; Gatenby et al, 1988; Okunieff et al, 1993). In addition, a
good correlation between the radiobiological hypoxic fraction and
oxygen electrode measurements has been reported in various
mouse tumour models to date (Horsman et al, 1994; Nordsmark et
al, 1995). Because ofthe surgical invasiveness ofoxygen electrode
measurements, however, the search continues for clinically rele-
vant surgically non-invasive methods for detecting hypoxia within
human tumours. In this regard, methods that use the bioreduction
and selective retention of 2-nitroimidazoles within hypoxic cells
(cells with pO2 < 10 mnmHg; radiobiological hypoxia < 1 mmHg)
have been used to detect these cells in spheroid culture or within
rodent and human tumours in vivo (Chapman et al, 1981;
Chapman, 1984; Mueller-Klieser et al, 1991; Raleigh et al, 1991;
Lord et al, 1993; Aboagye et al, 1995a; Kavanagh et al, 1996).
Fluorinated 2-nitroimidazoles probes, in particular, have been used
to detect hypoxia by magnetic resonance spectroscopy (MRS) or
imaging (MRI) (Maxwell et al, 1988; Jin et al, 1990; Raleigh et al,
1991; Kwock et al, 1992). Although the retention of these fluori-
nated nitroimidazoles within tumours has been investigated, the
relationship between the extent of selective binding and the
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oxygen tension (pO2) of tumours has not been reported to date.
This subject has been addressed in the present paper for the exper-
imental fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoro-
propyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554; Figure 1).
We have previously reported the subcellular localization and
retention of the fluorinated 2-nitroimidazole SR-4554 in A2780
human ovarian multicellular spheroids (Aboagye et al, 1995a)
with increased retention observed within hypoxic cells. In another
study, the retention of SR-4554 was shown to correlate with the
reported hypoxic fraction of mouse tumours and was sensitive to
modulation of tumour oxygenation by hydralazine and carbogen
(Aboagye et al, 1997). As a consequence of these and various
attractive features, including pharmacokinetic and toxicological
properties along with detection sensitivity (Aboagye et al, 1995a,
b; 1996), SR-4554 is currently being developed as a probe for
detecting tumour hypoxia by MRS/MRI. In this paper, we have
extended the work to investigate the relationship between the
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Figure 1 Chemical structure of SR-4554
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Figure 2 Typical 19F and 2H spectra obtained from a CH3 mammary flank tumour and external reference standard. (A) and (B) represent l9F spectra obtained
at 45 min and 6 h, respectively, after SR-4554 injection, whereas (C) and (D) represent the corresponding 2H spectra. SR-4554 was present in the tumour at
both 45 min and 6 h post-injection. The spectra also show the internal standard, natural abundance deuterium in tumour water (HOD), as well as the external
reference standards 5-fluorotryptophan (5-FTP) and acetic acid-d (AcOH-d)
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Table 1 The effect of SR-4554 and anaesthesia on the oxygenation of C3H mammary foot tumours implanted in female CDF1 mice
SR-4554a Anaesthesiab Tumour Mean Median 1O2values P°2 values P°2 values Number
treatment size P02 P02 < 2.5 mmHg < 5 mmHg . 10 mmHg of mice
(mm3) (mmHg) (%) (%) (%) (%) used
- - 215+123 6+1 2+1 62±5 69+4 79±3 7
+ - 214±12 9+1 5+1 29+5 62+5 73±5 5
+ 212+12 7+1 2+1 60±6 68±6 75+5 6
+ + 222+13 8+1 4±1 26+11 53±11 76+3 6
All results show mean + 1 s.e. The total number of P02 readings in each case were between 356 and 552, obtained from five to seven mice. P02 measurements
were made 1 h after SR-4554 administration and 40 min after anaesthesia. aSR-4554 prepared in saline was administered intraperitoneally at a dose of
180 mg kg-' body weight. bHypnorm-Hypnovel-water (1-1-2) was administered intraperitoneally at 0.01 ml g-1 body weight.
retention of SR-4554 in transplantable mouse tumours using MRS
andpO, measurements made with the oxygen electrode. The effect
of the compound SR-4554 alone on tumour oxygenation has also
been investigated. One important requirement in experimental
MRS/MRI studies is the immobilization of experimental animals.
There are currently two methods of immobilization commonly
used in most institutions, physical restraint and anaesthesia, the
latter being the more common ofthe two methods. As anaesthesia,
in particular, may affect the physiological state of the animals
(Zhao et al, 1995), we have also studied the effect of anaesthesia
on the oxygenation state of the tumour.
MATERIALS AND METHODS
Tumour models
A number of mouse tumour models with varying oxygen tensions
were used in this study. These included the C3H mouse mammary
carcinoma, which was implanted in the flank and feet of CDF,
mice, as well as RIF-1 and SCCVII tumours grown in the flank of
C3H/Km mice. The induction and maintenance of these tumours
have been reported previously (Overgaard, 1980; Twentyman et al,
1980; Olive and Durand, 1989).
MRS measurements
SR-4554 was synthesized and purified at SRI International, Menlo
Park, CA, USA (Aboagye et al, 1996). The compound was formu-
lated as a 3 mg kg-' solution in saline and injected intraperitoneally
at a dose of 180 mg kg-' (0.06 ml g-'). Mice were anaesthetized
(Hypnorm-Hypnovel-water; 1:1:2; 0.01 ml g-') 20 min after SR-
4554 injection. MR spectra were obtained on a 7-tesla (Sisco)
NMR spectrometer using a double-tuned ('9F/2H) circuit. '9F
signals from SR-4554 (in tumour) and 5-fluorotryptophan (in a
reference bulb) were measured at 45 min and 6 h after the injection
ofSR-4554. Absolute quantitation of '9F signal levels (due to drug
and hypoxic metabolites) was achieved by obtaining 2H spectra
from water (in the tumour) and acetic acid-d (in a reference bulb)
and comparing '9F and 2H signal intensities. The '9F retention
index of the hypoxia probe was defined as the ratio of '9F signal
level at 6 h to that at 45 min after the injection of SR-4554.
Oxygen electrode measurements
The pO0 measurements were performed using a fine-needle
oxygen electrode (Eppendorf, Hamburg, Germany). In general,
measurements were made on anaesthetized mice, but in studies
that were designed to investigate the effect of anaesthesia on
oxygenation physically restrained conscious mice were used.
Between four and seven parallel tracks were made in each tumour.
For each track, the electrode was inserted up to a depth of 1 mm
into the tumour and moved automatically through the tissue in
forward (0.7 mm increments) and backward (0.3 mm) steps before
measurements were taken. A total of 50-100 measurements were
made within each tumour. The results were expressed as median
pO0 and as the percentage ofpO2 values < 2.5, 5 and 10 mmHg.
For comparison between '9F retention and tumourpO0, electrode
measurements were carried out 3 h after SR-4554 injection
(between the two MRS measurements). To investigate the effect of
SR-4554 and anaesthesia on tumour oxygenation, however, pO,
measurements were performed 1 h after SR-4554 injection and
40 min after anaesthesia.
RESULTS
At 7 tesla, the '9F and 2H spectra from tumour and reference
samples were easily detected (Fig. 2). In general, SR-4554 levels
ofbetween 0.1 and 1 gmol g-' tissue were calculated. Figure 2 also
demonstrates that in a C3H mammary flank tumour, the '9F signal
intensity from SR-4554 was only slightly lower at 6 h than at
45 min, giving a '9F retention index of0.9.
Three tumour models, namely C3H-mammary, SCCVII and
RIF-1, were grown in two sites (foot and flank) and were character-
ized according to their '9F retention index andpO, status. The rela-
tionship between '9F retention index andpO, parameters including
median pO2 and the percentage of pO0 values <2.5, 5 and
10 mmHg are illustrated in Figure 3. Each point represents thepO,
and corresponding '9F measurement obtained from a single tumour.
Although the different tumour types showed relatively different
trends, in general high '9F retention index was associated with a low
medianpO0 and also with a high percentage ofpO2 values < 2.5, 5
or 10 mmHg. For example, a '9F retention index of > 0.5 corre-
sponded to a median pO2 < 2.5 mmHg (nine out of ten tumours)
and also to a percentage ofpO2 < 5 mmHg ofgreater than 60% (ten
out of ten tumours). However, of importance, no strong linear
correlation was foundbetweenpO2 parameters (medianP02 and the
percentage ofpO values < 2.5, 5 or 10 mmHg) and the 19F reten-
tion index for any one tumour type alone or for all tumour types
combined (r < 0.3). A high '9F retention index did not always corre-
late with lowpO2. For instance, the two extreme '9F retention index
values (> 1.5) corresponded to percentage ofpO0 values < 5 mmHg
of only 79% and 65%, whereas some tumours with a '9F retention
index of< 0.5 gave percentage ofpO2 values < 5 mmHg ofbetween
80% and 100%. The variability was particularly evident at low '9F
retention indices.
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Figure 3 Relationship between 19F retention index (ratio of 19F signal levels at 6 h to 45 min after SR-4554 injection) and P02 parameters (A) median,
(B) percent of P02 values < 2.5 mmHg, (C) percent of P02 values < 5 mmHg and (D) percent of P02 values < 10 mmHg. The P02 measurements were carried
out 3 h after SR-4554 injection (i.e. between the two 19F MRS measurements), as described in the Materials and methods section. Each point represents P02
and '9F measurements taken from individual C3H mammary foot tumours (1), C3H mammary flank tumours (O), SCCVII flank tumours (0) and RIF-1 flank
tumours (A). Tumour sizes (mean ± 1 s.e.) were 195 ± 2, 424 ± 13, 430 ± 19 and 377 ± 30 mm3 for C3H foot, C3H flank, SCCVII flank and RIF-1 flank tumours
respectively
To assess whether the determination of pO2 at a time point
midway between the two 19F measurements could affect the 19F
retention indices generated by the MRS technique, 19F experiments
were carried out in C3H mammary (flank) tumours with or
without pO2 measurements. No statistically significant difference
(Kruskal-Wallis test) was detected between the two groups
(means ± s.d. were 0.79 ± 0.8 and 0.64 ± 0.3 respectively).
To investigate whetherthe '9F-MR protocol used could influence
tumour hypoxia, pO2 measurements in SR-4554 treated vs
untreated and anaesthetized vs unanaesthetized mice were obtained
(Table 1). Statistical analysis ofthe data (Kruskal-Wallis test; 95%
confidence level) showed no significant differences between means
and the percentage of pO2 values < 5 and 10 mmHg. Significant
differences were, however, observed upon comparison of medians
and the percentage ofpO2 values < 2.5 nunHg. For instance, treat-
ment of the mice with SR-4554 resulted in an increase in median
tumour pO2 of 3 mmHg and a decrease in the percentage ofpO2
values < 2.5 mmHg equal to 33%.
DISCUSSION
Previous studies to find the relationship between 2-nitroimidazole
binding and oxygen tension (p02) have mainly been carried out in
vitro using cell lines or excised tumours (Koch et al, 1984; Franko
et al, 1987; Joseph et al, 1994). However, to use 2-nitroimidazoles
as non-invasive probes for tumour hypoxia an in vivo assessment
of such a relationship is required. For this reason, and to support
the development of SR-4554 as a hypoxia probe, the relationship
between '9F-MRS retention and tumourpO2 (measured directly by
Eppendorf oxygen needle electrode) was assessed in several trans-
plantable rodent tumours in vivo. The oxygen electrode method of
determining pO2 was chosen for comparison as the technique
directly measures pO2 and is currently being used clinically to
determine tumour oxygenation (Kolstad, 1968; Vaupel et al, 1991;
Okunieff et al, 1993; Rampling et al, 1994).
The extent of SR-4554 retention in tumours, which is related to
hypoxia-dependent reduction, was expressed as the 19F retention
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index. Specifically, MRS determination of total drug (at 45 min)
compared with bioreduced drug (at 6 h) provides an index of
the oxygenation status as HPLC studies have shown that original
drug is eliminated by 6 h after injection at the dose used
(Aboagye et al, 1996).
No strong linear correlations were observed when '9F retention
index and pO2 were compared (r < 0.3). The inability to observe a
strong correlation between the two techniques was not altogether
surprising as by using oxygen needle electrodes, low pO2 values
may also result from regions within the tumour that do not contain
viable hypoxic cells, such as necrotic regions, whereas 2-nitroimi-
dazoles label only hypoxic cells (Chapman et al, 1981; Lord et al,
1993; Aboagye et al, 1995a). This may also account for the higher
variability ofpO2 values at low '9F retention indices as the influ-
ence of necrosis on the average pO2 values obtained is potentially
high. Despite the lack ofoverall correlation noted above, the study
indicated that all tumours that showed substantial retention of '9F
signal ('9F retention index of> 0.5) also had a high level oftumour
hypoxia or low tumour oxygenation (% pO2 < 5 mmHg = 60%).
This observation is probably a result ofthe selective reductive acti-
vation of SR-4554 under such hypoxic conditions. Cytotoxicity of
the chemical probe towards hypoxic cells is unlikely to contribute
significantly to tumour oxygenation because nitroimidazoles such
as SR-4554, which do not incorporate a cytotoxic side-chain, have
very low cytotoxicity (Chapman et al, 1983). Previous studies in
C3H mammary foot tumours suggested that when the percentage
of PO2 values < 5 mmHg was 60% the equivalent clonogenic
radiobiological hypoxic fraction was 10% (Nordsmark et al,
1995). We might, therefore, speculate that substantial trapping of
the '9F signal could be evident in tumours with a radiobiological
hypoxic fraction of > 10%. This level of sensitivity is likely to be
of clinical relevance; for example, the radiocurability of human
tumours is reduced with the presence of . 26% of tumour cells
with pO2< 8 mmHg (Gatenby et al, 1988).
As part of the present study, it was necessary to investigate the
effect of anaesthesia on pO, as this form of restraint may be
required in experimental studies with SR-4554. Oxygen tension
measurements indicated that the anaesthetic used (Hypnorm-
Hypnovel-water) did not significantly alter tumour oxygenation in
the C3H mammary tumour model. This is consistent with our 31p
bioenergetic measurements (Nordsmark et al, 1995; M Nordsmark
et al, submitted for publication). Sansom and Wood (1994)
have also demonstrated the lack of significant 31p spectral changes
in anaesthetized (Hypnorm-Hypnovel-water) vs tumours in
conscious mice. These are very interesting findings as other widely
used anaesthetics, such as isoflurane and halothane, have been
shown to alter tumour characteristics including blood flow and
bioenergetics (Zhao et al, 1995). In contrast, however, SR-4554
alone and the combination of SR-4554 and anaesthetic produced a
small but significant increase in tumour oxygenation when medians
or the percentage ofpO0 values < 2.5 mmHg were compared. It is
unknown whether this effect ofSR-4554 is due to a direct effect on
the oxygen electrode, e.g. by an electrochemical effect, or specifi-
cally due to the effect of the compound on tumour oxygenation.
This interesting observation is, however, contrary to the decrease in
tumour blood flow (and hence oxygenation) produced by another
2-nitroimidazole, pimonidazole, at a dose of 500 mg kg-' body
weight in the same tumour model measured over I h (Chaplin
and Horsman, 1992). Provided the same anaesthesia/SR-4554
protocol is used in all experimental animal studies, however, this
increase in oxygenation produced by the combination of SR-4554
and anaesthesia will not be expected to affect the use ofSR-4554 to
measure tumour oxygenation. It is, nevertheless, an aspect that
should be investigated in any clinical trials with SR-4554.
An obvious concern in the design ofthe present experiments was
whether the measurement ofpO, in SR-4554 treated tumours will
alter the 19F data determined by MRS. Importantly, no significant
differences in '9F retention were observed between tumours that
had theirpO2 measured and those that did not (Kruskal-Wallis test;
95% confidence level), indicating that the pO2 measurements by
themselves did not significantly affect the retention of SR-4554.
An important consideration, which is relevant to the clinical
applicability of this '9F MRS method, is signal sensitivity. The
dose of drug used in this study (180 mg kg-') is non-toxic
(Aboagye et al, 1996), and up to 1300 mg kg-' can be safely
administered without any observable toxic effect in non-tumour-
bearing female Balb/c mice. This implies that the sensitivity of
detection can be further enhanced by the administration of higher
doses. With regard to signal sensitivity per mole of '9F, it is worth
mentioning that, although these experiments were carried out at
7 tesla, the compound is easily detectable at the same dose at
4.7 tesla. Similar experiments with the monofluorinated 2-nitro-
imidazole Ro 07-0741 at 1.9 tesla suggests that SR-4554 will be
detected using clinical MR instruments that are available currently
(1.5-4 tesla). Considering the feasibility of these methods in
patients, it should be noted that, even ifmagnetic field strength and
drug dosage were lower, tumour volume can be substantially
greater than in the murine tumours studied here.
In summary, the present studies have shown that the fluorinated
2-nitroimidazole SR-4554 has the ability to detect clinically rele-
vant levels of tumour hypoxia and have provided useful informa-
tion for the clinical development of SR-4554 as a non-invasive
probe for use in man. No single method is necessarily ideal for
measuring therapeutically relevant tumour hypoxia, as all have
potential advantages and disadvantages. The important require-
ment is to obtain information on the correlation with clinical
outcome in man.
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